We retrospectively analyzed the incidence and risk factors for veno-occlusive disease (VOD) in 83 consecutive children with solid tumors, who underwent autologous blood or bone marrow (BM) transplantation at UCSF between 1992 and 2000. Forty-one patients were diagnosed with neuroblastoma and 42 had another solid tumor (Ewing's sarcoma, soft tissue sarcomas, germ cell tumors, etc). Patients with neuroblastoma were more likely than patients with other solid tumors (ST) to be р7 years of age, to have a decreased serum albumin level, and to have received abdominal radiation and surgery prior to transplant. Patients with neuroblastoma received a different conditioning regimen and a purged stem cell product. Twenty patients (24%) developed VOD. VOD was self-limited in 15 (75%) patients and severe in five (25%) patients. Univariate analysis identified the following risk factors for VOD: diagnosis of neuroblastoma (odds ratio 6.1, P Ͻ 0.01), abdominal radiation (odds ratio 4.1, P Ͻ 0.01), abdominal surgery (odds ratio 4.1, P Ͻ 0.01), and age р7 years of age (odds ratio 3.3, P = 0.02). Disease status at transplant, intensity of previous chemotherapy, conditioning regimen, progenitor cell source, ALT, AST, albumin level, renal function prior to transplant, or use of amphotericin, growth-factor or heparin during transplant, did not affect the incidence of VOD. On multivariate analysis, only the diagnosis of neuroblastoma remained significant (odds ratio 7.8, P = 0.03). Larger studies of patients with neuroblastoma are necessary in order to confirm our findings and better define the risk factors for VOD development in neuroblastoma patients.
Veno-occlusive disease (VOD) of the liver is a clinical syndrome characterized by hepatomegaly, fluid retention and hyperbilirubinemia resulting from endothelial cell and hepatocyte damage during high-dose cytoreductive therapy. Despite well-described criteria for diagnosis of this disease, the incidence of VOD varies significantly (5-54%), indicating that different transplant cohorts may have different incidences of VOD. VOD occurs in patients undergoing autologous transplantation with an incidence of between 5 and 27%. [1] [2] [3] [4] [5] [6] Likewise, the risk factors for VOD vary from report to report. The most consistently identified risk factors include pre-existing liver dysfunction, advanced disease status at time of transplant, greater HLA disparity between donor and host, and use of higher intensity conditioning regimens. 3, 4 In our preliminary report, we identified a high incidence of VOD (41%) in children undergoing autologous transplantation for neuroblastoma. Contrary to this, children undergoing autologous transplant for other solid tumors had a relatively low incidence of VOD (9%). 7 The goal of the present study was to compare children with neuroblastoma to those undergoing autologous transplantation for other solid tumors, in order to identify risk factors that predispose to development of VOD.
Patients and methods
Eighty-three patients (mean age 7 years, range 0-22 years) with solid tumors undergoing autologous and syngeneic transplant at the Pediatric Bone Marrow Transplant Unit of the University of California, San Francisco, from January 1992 to December 2000, were enrolled in this study. Their diagnoses included neuroblastoma (49%), soft tissue sarcoma (12%), Ewing's sarcoma/PNET (8%), germ cell tumors (7%), Wilm's tumor (6%), brain tumors (6%), nonHodgkin's lymphoma (6%) and Hodgkin's lymphoma (6%). Demographic and transplantation data were collected from the pediatric BMT database and medical records.
Conditioning regimens
All patients received high-dose chemotherapy. The most common protocols (used for 92% of patients) included: (1) 2 (three ST patients -4%). Progenitor cell sources included purged and unpurged autologous bone marrow and peripheral blood, and in two cases, unpurged syngeneic bone marrow. All patients with neuroblastoma received immunomagnetic bead-purged progenitor cell products, with the exception of one patient who received a syngeneic bone marrow transplant. All patients with other ST received unpurged progenitor cell products, with the exception of two patients with non-Hodgkin's lymphoma who received 4-hydroperoxycyclophosphamide-purged progenitor cells. The method for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads has been previously described. 8 Carboplatin doses were adjusted for renal function Ͻ100 ml/min/1.73 m 2 using the modified Calvert formula.
Supportive care
All patients were placed in protective isolation from the start of conditioning therapy until myeloid engraftment (ANC Ͼ500 × 3 days). Prophylactic medications included intravenous acyclovir in patients with herpes seropositivity (500 mg/m 2 /day) given from admission until T cell function recovery, intravenous or oral fluconazole prophylaxis from admission until discharge (3 mg/kg/day), and 3 days per week Pneumocystis carinii prophylaxis with co-trimoxazole starting on day +15 until T cell recovery. Patients also received IVIG (200-400 mg/kg/4 weeks). At the first fever onset, broad-spectrum antibiotics were started, and amphotericin was used in patients who were persistently febrile for у3 days. Patients treated since 1995 received low-dose continuous heparin infusion (100 U/kg/day) prophylaxis for VOD from admission until day +30 or discharge, whichever came first. Myeloid growth factors (G-CSF and GM-CSF) were used in all patients from day 0.
Criteria for VOD
For the diagnosis of VOD, two of the following criteria had to be met within 20 days of transplantation: hyperbilirubinemia (total serum bilirubin Ͼ2 mg/dl (34 mol/l)), hepatomegaly or right upper quadrant pain of liver origin, and sudden weight gain (Ͼ2% of baseline body weight) secondary to fluid accumulation. No other explanation for these signs or symptoms could be present at the time of diagnosis of VOD. According to the criteria of McDonald et al, 3 VOD was retrospectively defined as severe if adverse effects from liver disease persisted after day +100 or if the patient died before day +100 with ongoing VOD. All other patients were considered to have self-limited VOD.
Treatment of VOD
Once a patient was diagnosed with VOD during transplant, VOD supportive care measures were instituted, including maintaining hemoglobin у10 gm/dl, maintaining albumin у3.0 gm/dl, and starting low-dose dopamine and/or diuretics to maintain urine output. There were no prospectively determined criteria for initiation of specific therapy for VOD; however, since 1993, bilirubin and weight gain were followed daily, and if a patient was developing severe VOD (based on Bearman's prediction model), 9 tissue plasminogen activator (tPA) was initiated (5-10 mg i.v. over 4 h daily for 4 days).
Statistical methods
Fisher's exact test and chi-square test were used when testing associations of independent categorical variables, and Student's t-test was used when testing associations of independent continuous variables. Two-tailed P value and odds ratios are presented, when appropriate. Multivariate analysis of risk factors used logistic regression. Two models were evaluated; in the first one, all variables with a P value of Ͻ0.1 on univariate analysis were entered in the regression model. In the second model, variables that had a strong intercorrelation with the variable 'diagnosis' were eliminated from the model (variables with P Ͻ 0.01 from Table 1 were eliminated from the second model). All data analyses were performed using the SPSS statistical program (Version 6.1 for Windows, SPSS, Chicago, IL, USA).
Results

Patient characteristics
Eighty-three children underwent autologous transplantation for solid tumors, 41 patients had neuroblastoma, and 42 some other solid tumor. All patients received intensive chemotherapy prior to transplantation. The time between the diagnosis and transplant was 9.8 Ϯ 7.8 months (mean Ϯ s.d.) for patients with neuroblastoma, and 16.6 Ϯ 18.6 months for patients with other solid tumors (P for twotailed t-test Ͻ0.01). Eighty percent of patients received surgery and radiation therapy in addition to chemotherapy. Only one patient was seropositive for hepatitis B prior to transplant, and only one patient had an elevated alkaline phosphatase prior to transplant. Twenty-two patients (26.5%) were seropositive for CMV. Heparin was used for VOD prophylaxis in 69 (83.1%) patients. Twenty patients (24.1%) developed VOD during transplant, five of whom had severe VOD. Table 1 presents the differences between patients with neuroblastoma and other solid tumors. Patients with neuroblastoma were more likely than other patients to be younger (mean age 5.09 Ϯ 3.8 years vs 10.07 Ϯ 5.7 years, P Ͻ 0.01), to have received abdominal radiation (78% vs 11%, P Ͻ 0.01) and abdominal surgery (88% vs 26%, P Ͻ 0.01) prior to transplant, and to have had decreased serum albumin values prior to transplant (58% vs 29%, P = 0.02). During transplant, patients with neuroblastoma were more likely to have received melphalan/etoposide/carboplatin conditioning (93% vs 2%, P Ͻ 0.01), purged stem cell products (98% vs 5%, P Ͻ 0.01) and have received G-CSF as a growth factor (63% vs 33%, P Ͻ 0.01). Patients with neuroblastoma were significantly more likely to develop VOD during transplant (39% vs 10%, P Ͻ 0.01). There was no difference between patients with neuroblastoma and other autologous transplants with respect to the amount of residual disease at the time of transplant, number of chemotherapy cycles prior to transplant, renal function prior to transplant, baseline ALT or AST value or use of amphotericin or heparin prophylaxis during transplant.
Univariate analysis of risk factors
The univariate analysis of risk factors for VOD is presented in Table 2 . Adverse risk factors for the development of VOD in transplant included the diagnosis of neuroblastoma (odds ratio 6.1, P Ͻ 0.01), age р7 years of age (odds ratio 3.3, P = 0.02), receiving either intraoperative or external beam radiation therapy to the abdomen prior to transplant (odds ratio 4.1, P Ͻ 0.01) and undergoing abdominal surgery (odds ratio 4.1, P = 0.01).
Multivariate risk factor analysis
Two logistic regression models were analyzed. First, all variables with a P value of р0.1 on univariate analysis were entered into the model. None of the entered variables was a significant predictor of VOD risk. In the second model, variables with P Ͻ 0.1 that were not intercorrelated with the variable 'diagnosis' were entered into the logistic regression model. Variables included were: diagnosis (other ST vs neuroblastoma), number of chemotherapy cycles prior to transplant (р4, 5-7, у8) and GFR (Ͼ100 vs р100 ml/min/1.73 m 2 ). The diagnosis of neuroblastoma was the only significant risk factor for development of VOD (odds ratio 7.8, P = 0.03).
Characteristics and outcomes of patients with VOD
Twelve patients with neuroblastoma and three patients with other ST had self-limited VOD, and four patients with neuroblastoma and one with Wilms tumor had severe VOD. Mean maximum total bilirubin was 5.9 Ϯ 2.8 mg/dl (s.d.) in patients with self-limited VOD and 24.7 Ϯ 7.6 mg/dl (s.d.) in patients with severe VOD (P Ͻ 0.01). Eight of 15 patients (53%) with self-limited VOD had renal insufficiency, seven had creatinine levels that were elevated for age, and one patient required dialysis due to renal failure during a septic episode. In the group of patients with severe VOD, 4/5 had renal insufficiency, 3/5 had an elevated creatinine and one required dialysis. In the group of patients with self-limited VOD, 2/15 (13%) required intubation (one for sepsis and another for lung hemorrhage). In the group of patients with severe VOD, 3/5 required intubation. None of the patients with self-limited VOD received specific treatment for VOD. Of five patients with severe VOD, four received tPA, one received defibrotide after tPA, and one received AT-III after TPA. One patient with severe VOD did not receive tPA due to bleeding complications. Three out of five patients with severe VOD are alive 47, 18 and 14 months post transplant. The maximum bilirubin levels of these surviving patients were 21.6, 27.3 and 35.0 mg/dl. Death within 100 days post transplant from transplantrelated complications was 15% (3/20) in the group of patients with VOD and 5% (3/63) in patients without VOD. However, overall survival (mean follow-up of 47.8 Ϯ 28 (s.d.) months post transplant) was 57% (36/63) in the group of patients without VOD, and 65% (13/20) in the group of patients with VOD. Table 3 summarizes the incidence and risk factors for VOD, identified in studies which included Ͼ50 ABMT patients. The incidence of VOD varies from study to study. The highest incidence of VOD has been reported from the Seattle group (37-54%, with the incidence of severe VOD 10-15%). 3, 15 The reasons for such a high incidence in the Seattle group's reports are multiple and may include a higher proportion of patients undergoing allogeneic and unrelated transplants, prospective follow-up for signs of disease, or possibly a lack of heparin prophylaxis. In many studies, patients undergoing ABMT had a lower incidence of VOD than those undergoing allogeneic transplantation. [11] [12] [13] [14] In our preliminary report on the incidence and risk factors for VOD, patients undergoing ABMT were divided into two distinct groups. Patients with neuroblastoma had a very high incidence of VOD (41%) while those undergoing ABMT for other solid tumors had a low incidence of VOD (9%). 7 The high incidence of VOD in children with neuroblastoma was not recognized in a large multi-institutional neuroblastoma treatment study, which used NCI Common toxicity criteria for grading liver toxicity and which reported the incidence of VOD to be 9%. 16 Possible reasons for the lower incidence of VOD in this large prospective study include lower dose of conditioning chemotherapy used, the multi-institutional nature of the study and data collection, and use of different criteria for the diagnosis of VOD. Although self-limited VOD does not affect overall survival, it may be important to recognize the signs of VOD early and predict its severity, since early intervention may decrease VOD-related mortality. However, studies to prove this hypothesis are still underway.
Discussion
Many risk factors for the development of VOD are described in the literature and include surrogate markers of pre-existing liver damage and indicators of liver function prior to conditioning, such as baseline hepatitis seropositivity, transaminase levels, pseudocholinesterase and albumin levels; 3, 17, 18 and markers of liver damage during conditioning by drugs or cytokines, such as intensity of cytoreductive therapy, use of methotrexate and cyclosporine during transplantation, use of antimicrobials during conditioning or hyalurinic acid levels. 3, 19 Our study did not have sufficient power to confirm the significance of factors such as baseline albumin, AST/ALT levels, or hepatitis seropositivity. Factors identified as significant on univariate analysis, such as age р7 years, surgery and radiation to the abdomen were strongly linked to the diagnosis of neuroblastoma and therefore not informative when added to the multivariate model. Allogeneic transplant, elevated AST, decreased Karnofsky score, lack of prophylaxis with heparin a 27% was the incidence in the entire cohort, the incidence of VOD in ABMT was not significantly different fromthe one in allogeneic BMT.
Similarly, given that almost all neuroblastoma patients received purged stem cell products, we could not evaluate whether purging of stem cells could have contributed to the higher incidence of VOD observed in neuroblastoma patients. This question might be answered with the ongoing prospective COG study in which patients with neuroblastoma are randomized to receive purged vs unpurged stem cell products. Due to the large number of induction and conditioning regimens used, our study did not have sufficient power to evaluate any possible contribution of type or dose of chemotherapy to the risk of VOD. Although this study did not have the power to identify risk factors other than the diagnosis of neuroblastoma, it is likely that a combination of factors, such as intensity of chemotherapy prior to transplant, abdominal surgery and radiation prior to transplant, as well as intensity of conditioning regimen given to this group of patients contributed to such a high risk of VOD. Larger numbers of patients with neuroblastoma will need to be studied to further define risk factors for VOD and establish whether modification of pre-transplant treatments, such as postponing of abdominal irradiation until after transplant, may affect the risk of VOD. In our study, as in previous studies of autologous transplants, continuous heparin infusion did not prevent liver VOD. 10, 12 VOD was linked to higher transplantrelated mortality at 100 days post transplant; however, it did not affect long-term survival.
In conclusion, in a retrospective analysis of children with solid tumors undergoing ABMT, patients with neuroblastoma had a significantly higher risk of VOD than did patients with other solid tumors. Further studies are necessary to confirm this finding as well as to better define risk factors for development of VOD in neuroblastoma patients.
